Management of Abdominal Bruising and Subcutaneous Lump in Patients on Enoxaparin

Assessment and Management

For patients on enoxaparin who develop abdominal bruising and a superficial subcutaneous lump, discontinuation of enoxaparin and evaluation for hematoma formation is recommended, with consideration of alternative anticoagulation if clinically necessary, as suggested by the American College of Cardiology 1
Complete blood count to assess for anemia from blood loss, and coagulation studies including platelet count to rule out heparin-induced thrombocytopenia (HIT), are recommended by the Mayo Clinic 2

If anticoagulation must be continued due to high thromboembolic risk, consider switching to unfractionated heparin with careful monitoring, as recommended by the American Heart Association 4
Alternative anticoagulants such as fondaparinux may be considered, which has a lower risk of causing hematomas, according to the Mayo Clinic 5
For patients with mechanical heart valves or other high thrombotic risk conditions, bridging with intravenous unfractionated heparin may be necessary, as suggested by the European Society of Cardiology 3

Monitor platelet counts in high-risk patients (orthopedic surgery) every 2-3 days from day 4 to day 14 of therapy, as recommended by the Mayo Clinic 2
Avoid adding additional anticoagulants to patients already on enoxaparin, as this significantly increases bleeding risk, according to the American College of Cardiology 1
Do not use activated clotting time (ACT) to guide anticoagulation in patients on enoxaparin, as low-molecular-weight heparins have minimal effect on ACT measurements, as stated by the American Heart Association 6